AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1448587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler treatment (1 mg of terbutaline and 80 micrograms of ipratropium bromide four times daily)
Number of subjects: 49
Study 1448587 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol nebulizer solution (5 mg)
Number of subjects: 49
Study 1448587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulizer (0.5 mg)
Number of subjects: 49
Study 1448587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nebulizer treatment (salbutamol and ipratropium bromide)
Number of subjects: 49
Study 1448587 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nebulizer treatment (chosen by patients)
Number of subjects: 49
Study 1448587 — intervention group
Group type: COMPARATOR
Intervention: Usual inhaled treatment (2 weeks prior to intervention)
Number of subjects: 49
Study 4061709 — intervention group
Group type: EXPERIMENTAL
Intervention: American Lung Association's Freedom From Smoking Manual
Number of subjects: 309
Study 4061709 — intervention group
Group type: EXPERIMENTAL
Intervention: A Pregnant Woman's Self‐Help Guide to Quit Smoking
Number of subjects: 309
Study 4061709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 309
Study 30074540 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 vaccine first dose at <6 weeks
Number of subjects: 10455
Study 30074540 — intervention group
Group type: EXPERIMENTAL
Intervention: RV1 vaccine with a 4-week interval between doses
Number of subjects: 10455
Study 30074540 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 vaccine first dose at 3-4 weeks
Number of subjects: 10455
Study 30074540 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 vaccine first dose at 5-7 weeks
Number of subjects: 10455
Study 30074540 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 vaccine first dose at 8 weeks
Number of subjects: 10455
Study 27232895 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully masked to lens and packaging (FM)
Number of subjects: 96
Study 27232895 — intervention group
Group type: COMPARATOR
Intervention: Unmasked (UM)
Number of subjects: 96
Study 27232895 — intervention group
Group type: COMPARATOR
Intervention: Partially masked using an over-label (PM)
Number of subjects: 96
Study 24669015 — intervention group
Group type: EXPERIMENTAL
Intervention: TR-FEC (paclitaxel 80 mg/m(2) i.v. and everolimus 30 mg PO weekly for 12 weeks, followed by FEC)
Number of subjects: 50
Study 24669015 — intervention group
Group type: COMPARATOR
Intervention: T-FEC (paclitaxel 80 mg/m(2) i.v. weekly for 12 weeks, followed by FEC)
Number of subjects: 50
Study 24669015 — intervention group
Group type: EXPERIMENTAL
Intervention: TR-FEC
Number of subjects: 50
Study 24669015 — intervention group
Group type: COMPARATOR
Intervention: T-FEC
Number of subjects: 50
Study 22075375 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (YNB)
Number of subjects: 0
Study 22075375 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 20122338 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term mobile phone users
Number of subjects: 162
Study 20122338 — intervention group
Group type: COMPARATOR
Intervention: Control group (never used mobile phones)
Number of subjects: 162
Study 18005366 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgative combined with simethicone (P-S group)
Number of subjects: 90
Study 18005366 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgative (PEG group)
Number of subjects: 90
Study 18005366 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 L clear liquids)
Number of subjects: 90
Study 18005366 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgative group (1 L PEG)
Number of subjects: 90
Study 18005366 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 16324245 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical resection of septum (TCRS)
Number of subjects: 111
Study 12021836 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 20
Study 12021836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9930904 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS-synchronous low-energy shocks (0.2, 0.4, 0.6, and 2.0 J)
Number of subjects: 25
Study 9930904 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS-synchronous low-energy shocks
Number of subjects: 25
Study 9930904 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS-synchronous low-energy shocks before atropine
Number of subjects: 25
Study 9930904 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 25
Study 9930904 — intervention group
Group type: COMPARATOR
Intervention: Atropine (2.0 mg intravenously)
Number of subjects: 25
Study 7566240 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 91
Study 7566240 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 91
Study 2288490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of ethanol
Number of subjects: 44
Study 2288490 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 44
Study 6112538 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 53
Study 6112538 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 53
Study 30685675 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (proprotein convertase subtilisin‐kexin type 9 inhibitor)
Number of subjects: 233977
Study 30685675 — intervention group
Group type: COMPARATOR
Intervention: Moderate-/high-intensity statins
Number of subjects: 233977
Study 28366648 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diagnostic approach
Number of subjects: 903
Study 28366648 — intervention group
Group type: COMPARATOR
Intervention: Open strategy
Number of subjects: 903
Study 27199179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersession process (ISP) characteristics during outpatient psychotherapy for AN
Number of subjects: 108
Study 24984998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie, low-carbohydrate soy-containing diet
Number of subjects: 45
Study 24984998 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie, low-carbohydrate diet
Number of subjects: 45
Study 24984998 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 45
Study 21131864 — intervention group
Group type: COMPARATOR
Intervention: 25 g of whey protein (PRO)
Number of subjects: 9
Study 21131864 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of whey protein plus 50 g of maltodextrin (PRO+CARB)
Number of subjects: 9
Study 21131864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRO and PRO+CARB
Number of subjects: 9
Study 21131864 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of CHO with 25 g of protein (PRO+CARB)
Number of subjects: 9
Study 19438818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent terbinafine (TOT) 250 mg/day for 4 weeks followed by 4 weeks off, then 4 weeks of 250 mg/day
Number of subjects: 105
Study 19438818 — intervention group
Group type: COMPARATOR
Intervention: Continuous terbinafine (CTERB) 250 mg/day for 12 weeks
Number of subjects: 105
Study 19438818 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (III) pulse of 200 mg twice daily for 7 days on, 21 days off, three pulses
Number of subjects: 105
Study 16484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytostatic antineoplastic agents
Number of subjects: 0
Study 16484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Well designed descriptive studies
Number of subjects: 0
Study 15051778 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron (iron dextran repeated 100mg IV bolus)
Number of subjects: 157
Study 15051778 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron (iron dextran total dose infusion)
Number of subjects: 157
Study 15051778 — intervention group
Group type: COMPARATOR
Intervention: No-iron
Number of subjects: 157
Study 15051778 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (325 mg twice daily)
Number of subjects: 157
Study 11248568 — intervention group
Group type: COMPARATOR
Intervention: Patella tendon autograft (Group PT)
Number of subjects: 60
Study 11248568 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus/gracilis autograft (Group SG)
Number of subjects: 60
Study 9152680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 209 micromol of Vitamin A
Number of subjects: 50
Study 7957533 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg orlistat
Number of subjects: 173
Study 7957533 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg orlistat
Number of subjects: 173
Study 7957533 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg orlistat
Number of subjects: 173
Study 7957533 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg orlistat
Number of subjects: 173
Study 7957533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 3666662 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 630
Study 3666662 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 630
Study 31990087 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK‐954 (0.5 mg intravenous over 1 hour)
Number of subjects: 13
Study 31990087 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg intravenous 4 times/d)
Number of subjects: 13
Study 31990087 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK‐954
Number of subjects: 13
Study 31990087 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 13
Study 29164826 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 50% glycolic acid (pH 3.0) + 0.5% salicylic acid solution
Number of subjects: 20
Study 29164826 — intervention group
Group type: COMPARATOR
Intervention: Jessner's solution
Number of subjects: 20
Study 27055733 — intervention group
Group type: EXPERIMENTAL
Intervention: MPMI-2 X
Number of subjects: 196
Study 27055733 — intervention group
Group type: EXPERIMENTAL
Intervention: MPMI-1 X
Number of subjects: 196
Study 27055733 — intervention group
Group type: COMPARATOR
Intervention: MTF
Number of subjects: 196
Study 27055733 — intervention group
Group type: COMPARATOR
Intervention: Envelope flap
Number of subjects: 196
Study 24006155 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+HP+CVVHDF
Number of subjects: 19
Study 24006155 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+CVVHDF
Number of subjects: 19
Study 24006155 — intervention group
Group type: EXPERIMENTAL
Intervention: HP+CVVHDF
Number of subjects: 19
Study 22092688 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patch (pulsed electromagnetic energy)
Number of subjects: 57
Study 22092688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 57
Study 20832803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Mechanisms responsible for dynamic stability (n=13)
Number of subjects: 38
Study 20832803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Mechanisms of dynamic stability and muscle strength (n=13)
Number of subjects: 38
Study 20832803 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 38
Study 18503714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (7 mg/kg body weight, every eight hours)
Number of subjects: 50
Study 18503714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16977953 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray)
Number of subjects: 70
Study 16977953 — intervention group
Group type: EXPERIMENTAL
Intervention: ABF (Protect Bond) (Kuraray)
Number of subjects: 70
Study 16977953 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multipurpose Plus (3M/ESPE)
Number of subjects: 70
Study 16977953 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (Dentsply)
Number of subjects: 70
Study 16977953 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Self‐Etch (Kerr)
Number of subjects: 70
Study 16977953 — intervention group
Group type: EXPERIMENTAL
Intervention: OneCoatSE Bond (Colténe Whaledent)
Number of subjects: 70
Study 16977953 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond (Heraeus‐Kulzer)
Number of subjects: 70
Study 14592323 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch_PAT100 (WP100) device measuring PAT, oximetry and actigraphy
Number of subjects: 68
Study 14592323 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch_PAT100 (WP100) device measuring PAT
Number of subjects: 68
Study 10913472 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 25
Study 10913472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8712823 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 2 courses of chemotherapy with CDDP and VDS
Number of subjects: 94
Study 8712823 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: UFT daily for 1 year after 2 courses of CDDP
Number of subjects: 94
Study 8712823 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Intrapleural administration of OK-432 after lung resection, then UFT and OK-432 once every 2 weeks for 1 year
Number of subjects: 94
Study 8712823 — intervention group
Group type: COMPARATOR
Intervention: Group A (noncurative resection)
Number of subjects: 94
Study 8712823 — intervention group
Group type: COMPARATOR
Intervention: Group A (low-grade TP <6.0 g/dl or low response of PPD skin reaction <12mm)
Number of subjects: 94
Study 1574292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injection of sodium hyaluronate (HA) in group B (11 patients)
Number of subjects: 22
Study 1574292 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy in group A (11 patients)
Number of subjects: 22
Study 3904559 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/d for 8 weeks)
Number of subjects: 80
Study 3904559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 daily supplements (50 μg) to pregnant women
Number of subjects: 0
Study 30782904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30297500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizer group (HSG; n = 339)
Number of subjects: 911
Study 30297500 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water group (SWG; n = 274)
Number of subjects: 911
Study 30297500 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 298)
Number of subjects: 911
Study 26612392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 7 nights of 5 hours time in bed (TIB)
Number of subjects: 56
Study 26612392 — intervention group
Group type: COMPARATOR
Intervention: Control - 7 nights of 9 hours time in bed (TIB)
Number of subjects: 56
Study 24577860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated (DEH, -3.8±0.5%)
Number of subjects: 7
Study 24577860 — intervention group
Group type: COMPARATOR
Intervention: Rehydrated (REH, 0.2±0.6%)
Number of subjects: 7
Study 22653560 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning (SBL)
Number of subjects: 29
Study 22653560 — intervention group
Group type: COMPARATOR
Intervention: Problem-based learning (PBL)
Number of subjects: 29
Study 19765202 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental care coordinator intervention
Number of subjects: 136
Study 19765202 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine Medicaid member services)
Number of subjects: 136
Study 17513708 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin regimen (glargine and glulisine)
Number of subjects: 130
Study 17513708 — intervention group
Group type: COMPARATOR
Intervention: Sliding-scale regular insulin (SSI)
Number of subjects: 130
Study 15390055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.125 mg rotigotine (RTG) per day
Number of subjects: 63
Study 15390055 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25 mg rotigotine (RTG) per day
Number of subjects: 63
Study 15390055 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg rotigotine (RTG) per day
Number of subjects: 63
Study 15390055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 15390055 — intervention group
Group type: EXPERIMENTAL
Intervention: All rotigotine doses
Number of subjects: 63
Study 15390055 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg rotigotine (RTG)
Number of subjects: 63
Study 15390055 — intervention group
Group type: COMPARATOR
Intervention: Rotigotine and placebo
Number of subjects: 63
Study 11696145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 32
Study 11696145 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 32
Study 11696145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCV and VCV
Number of subjects: 32
Study 9882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 12.5 mg
Number of subjects: 0
Study 9882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg
Number of subjects: 0
Study 9882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 0
Study 9882084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 12.5 mg and 25 mg, Ketoprofen 50 mg
Number of subjects: 0
Study 9882084 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 9882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen and Ketoprofen
Number of subjects: 0
Study 8018673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of beta-carotene
Number of subjects: 0
Study 8018673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2553940 — intervention group
Group type: EXPERIMENTAL
Intervention: soya milk formula
Number of subjects: 19
Study 2553940 — intervention group
Group type: COMPARATOR
Intervention: standard modified cows milk formula
Number of subjects: 19
Study 2553940 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrolysed protein milk
Number of subjects: 19
Study 2553940 — intervention group
Group type: EXPERIMENTAL
Intervention: dietary change
Number of subjects: 19
Study 973819 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% eyedrops
Number of subjects: 18
Study 973819 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% eyedrops
Number of subjects: 18
Study 973819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mug/hr ocular therapeutic system
Number of subjects: 18
Study 973819 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mug/hr ocular therapeutic system
Number of subjects: 18
Study 31172415 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN and vaccine for 48 weeks plus IL-2 for 12 weeks (group III)
Number of subjects: 94
Study 31172415 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN for 48 weeks (group II)
Number of subjects: 94
Study 31172415 — intervention group
Group type: COMPARATOR
Intervention: ETV for 48 weeks (group I)
Number of subjects: 94
Study 31172415 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (IFN and vaccine plus IL-2) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Number of subjects: 94
Study 31172415 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (IFN) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Number of subjects: 94
Study 31172415 — intervention group
Group type: COMPARATOR
Intervention: Group I (ETV) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Number of subjects: 94
Study 29090311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus-matched (TM)
Number of subjects: 60
Study 29090311 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise stimulus (NS)
Number of subjects: 60
Study 29090311 — intervention group
Group type: COMPARATOR
Intervention: Bedside sound generator (BSG)
Number of subjects: 60
Study 26369563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 5 μg
Number of subjects: 1370
Study 26369563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 2.5 μg
Number of subjects: 1370
Study 26369563 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium HandiHaler® 18 μg
Number of subjects: 1370
Study 26369563 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1370
Study 23891741 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2mA, 35 cm², 20min, once a week for five consecutive weeks)
Number of subjects: 13
Study 23891741 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 13
Study 23891741 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: IV + Hylo-Comod (HC) eye drops
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: IV + Vidisic (VS) eye drops
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment bandage (OB)
Number of subjects: 30
Study 22231764 — intervention group
Group type: COMPARATOR
Intervention: IV therapy alone
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: IV + OB
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: IV + HC or IV + VS
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: OB
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity artificial tears
Number of subjects: 30
Study 22231764 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity tear substitute
Number of subjects: 30
Study 19628143 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic screening approach
Number of subjects: 699
Study 19628143 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy relationship screening approach
Number of subjects: 699
Study 19628143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional screening approach
Number of subjects: 699
Study 19628143 — intervention group
Group type: COMPARATOR
Intervention: All screening approaches
Number of subjects: 699